Drug & Cancer & Variant
Result
Search content: Gene = AKT2
There are 2 entries with your keyword(s).
Gene Variant Type Tumor Drug Drug level Reference More
AKT2 AMP CNA Lung Adenocarcinoma Vandetanib+Everolimus IV 1
Evidence region

CIVIC

Patient Criteria

-

Note

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.

Gene name

AKT2

Full name

AKT serine/threonine kinase 2

Gene type

protein-coding

Function

This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019]

Drug name

Vandetanib

DrugBank ID

DB05294

Synonyms

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Vandetanib

Brand

Vandetanib
Caprelsa

Description

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Target gene
GeneFunction
VEGFAinhibitor
EGFRinhibitor
PTK6inhibitor
TEKinhibitor
RETUnknown

Drug name

Everolimus

DrugBank ID

DB01590

Synonyms

40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Everolimus
évérolimus

Brand

Certican
Sandoz Everolimus
Zortress
Votubia
Everolimus
Afinitor
PMS-everolimus
Teva-everolimus
Afinitor Disperz

Description

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Target gene
GeneFunction
MTORinhibitor
AKT2 AMP CNA All Tumor Types MK-2206 V 1
Evidence region

CGI

Patient Criteria

-

Note

-

Gene name

AKT2

Full name

AKT serine/threonine kinase 2

Gene type

protein-coding

Function

This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019]

Sorry, there is no related drug information.

Showing 1 to 2 of 2 entries, entries per page